Home » Stocks » RYTM

Rhythm Pharmaceuticals, Inc. (RYTM)

Stock Price: $20.09 USD 0.38 (1.93%)
Updated Apr 19, 2021 2:07 PM EDT - Market open
Market Cap 989.07M
Revenue (ttm) n/a
Net Income (ttm) -134.00M
Shares Out 44.13M
EPS (ttm) -3.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $20.09
Previous Close $19.71
Change ($) 0.38
Change (%) 1.93%
Day's Open 19.44
Day's Range 19.25 - 20.11
Day's Volume 194,568
52-Week Range 17.27 - 43.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.

Other stocks mentioned: AGRX, CMPI, CYTH, GORO, WINT, WMPN
1 week ago - InvestorPlace

BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic di...

1 week ago - GlobeNewsWire

-- Responders with HET obesity achieved mean weight loss of greater than 12 percent at nine months on setmelanotide therapy -- -- Additional poster presentations include Phase 3 data in Bardet-Biedl and...

4 weeks ago - GlobeNewsWire

BOSTON, March 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic di...

1 month ago - GlobeNewsWire

-- Received FDA approval of IMCIVREE™ (setmelanotide), the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency -- -- Announced positive toplin...

1 month ago - GlobeNewsWire

BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic dis...

2 months ago - GlobeNewsWire

BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic dis...

2 months ago - GlobeNewsWire

BOSTON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic dis...

2 months ago - GlobeNewsWire

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic dise...

3 months ago - GlobeNewsWire

-- Study met primary endpoint and all key secondary endpoints with statistically significant and clinically meaningful reductions in weight and hunger -- -- All primary endpoint responders were patients...

3 months ago - GlobeNewsWire

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic dise...

4 months ago - GlobeNewsWire

Rhythm's (RYTM) stock gains as FDA approves its lead product candidate for chronic weight management.

4 months ago - Zacks Investment Research

-- Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing -- -- Approval support...

4 months ago - GlobeNewsWire

-- Interim d ata from Phase 2 study showed that once-weekly formulation of setmelanotide achieve d safety and efficacy results comparable to daily-dosing formulation -- -- Additional data from long-term...

5 months ago - GlobeNewsWire

-- NDA for setmelanotide for POMC and LEPR deficiency obesities under review, with PDUFA goal date of November 27, 2020 --  -- Appointed Jennifer Chien and Yann Mazabraud to co-lead global integrated co...

5 months ago - GlobeNewsWire

Largest studies in POMC and LEPR deficiency obesities demonstrate that treatment with setmelanotide reduced body weight and hunger Largest studies in POMC and LEPR deficiency obesities demonstrate that ...

5 months ago - GlobeNewsWire

BOSTON, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare g...

5 months ago - GlobeNewsWire

Rhythm Pharmaceuticals (RYTM) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

– Company announces organizational changes designed to accelerate global strategy –

7 months ago - GlobeNewsWire

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of ra...

7 months ago - GlobeNewsWire

Rhythm (RYTM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rar...

8 months ago - GlobeNewsWire

-- Appointed David Meeker, M.D., as President and Chief Executive Officer –

8 months ago - GlobeNewsWire

BOSTON, July 27, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare...

8 months ago - GlobeNewsWire

BOSTON, July 20, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare...

8 months ago - GlobeNewsWire

-- Study demonstrated that treatment with setmelanotide reduced body weight and hunger in individuals living with Bardet-Biedl syndrome -- BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceut...

9 months ago - GlobeNewsWire

BOSTON, July 01, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare...

9 months ago - GlobeNewsWire

Rhythm's Setmelanotide Data And Other News: The Good, Bad And Ugly Of Biopharma

9 months ago - Seeking Alpha

-- Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation –

9 months ago - GlobeNewsWire

– FDA grants Priority Review of application and sets PDUFA goal date of November 27, 2020 –

11 months ago - GlobeNewsWire

 Hunter Smith, Chief Financial Officer, appointed Interim Chief Executive Officer following completion of NDA submission to FDA 

1 year ago - GlobeNewsWire

BOSTON, March 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of ra...

1 year ago - GlobeNewsWire

BOSTON, March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of ra...

1 year ago - GlobeNewsWire

Shares of Rhythm Pharmaceuticals Inc. RYTM, -2.64% were down 3% in trading on Tuesday, the day after the company announced that president and CEO Keith Gottesdiener plans to step down.

1 year ago - Market Watch

Keith Gottesdiener, M.D. to Step Down as Chief Executive Officer Following NDA Submission for Setmelanotide in POMC and LEPR Deficiency Obesities Expected in the First Quarter of 2020

1 year ago - GlobeNewsWire

-- Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 -- -- Supplemental cohort continues enrollment to meet patient demand --

1 year ago - GlobeNewsWire

Rhythm Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

BOSTON, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of ...

1 year ago - GlobeNewsWire

BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of ...

1 year ago - GlobeNewsWire

BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of ...

1 year ago - GlobeNewsWire

Liver Therapy Forum weekly digest provides an overview of what's happening in therapeutics for obesity in 2019. The focus this week is Rhythm Pharmaceuticals.

1 year ago - Seeking Alpha

-- Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients -- -- Genetic sequencing of 13,567 individuals with severe obesity yields 11.7 percent (1,584 individ...

1 year ago - GlobeNewsWire

-- Plan to expand ongoing Phase 2 Basket Study with four additional rare indications -- -- Sequenced nearly 14,000 people with early-onset, severe obesity; Yield suggests potential significant opportuni...

1 year ago - GlobeNewsWire

BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic d...

1 year ago - GlobeNewsWire

About RYTM

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC... [Read more...]

Industry
Biotechnology
IPO Date
Oct 5, 2017
CEO
Keith Gottesdiener
Employees
90
Stock Exchange
NASDAQ
Ticker Symbol
RYTM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for RYTM stock is "Buy." The 12-month stock price forecast is 46.25, which is an increase of 130.21% from the latest price.

Price Target
$46.25
(130.21% upside)
Analyst Consensus: Buy